A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use

Applied Health Economics and Health Policy

Volumn 11, Issue 3, 2013, Pages 259-274

  Price, David ^a   Asukai, Yumi ^b   Ananthapavan, Jaithri ^b   Malcolm, Bill ^c   Radwan, Amr ^c   Keyzor, Ian ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b IQVIA   (United States)

^c Novartis Pharmaceuticals UK Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDACATEROL; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MORTALITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNITED KINGDOM;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GREAT BRITAIN; HUMANS; INDANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84878747810     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0021-5     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011) (online). http://www.goldcopd.org/uploads/users/files/ GOLD-Report-2011-Jan21.pdf. Accessed 23 Jan 2012.
2. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). This guideline partially updates and replaces NICE clinical guideline 12 (online). http://guidance.nice.org.uk/CG101/NICEGuidance/pdf/English. Accessed 23 Jan 2012.
3. Department of Health /Medical Directorate/Respiratory Team. Consultation on a strategy for services for chronic obstructive pulmonary disease (COPD) in England (online). http://www.pcrs-uk.org/copd-qrg/qrg
4. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-62.
5. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-9.
6. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11(1):135.
7. Optimum Patient Care. The optimum patient care research database. 2012 (data on file).
8. Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011;105(11):1635-47.
9. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (online). http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf Accessed 20 Jan 2012.
10. Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23(2):241-9.
11. Oostenbrink JB, Rutten-van Molken MPH, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8(1):32-46.
12. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ. 2007;8(2):123-35.
13. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med. 2004;116(5):325-31.
14. Penning-van Beest F, van Herk-Sukel M, Gale R, et al. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. 2011;105(2):259-65.
15. Rutten-van Molken M, Lee TA. Economic modelling in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;3:630-4.
16. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
17. Office of National Statistics. United Kingdom, Interim Life Tables, 1980-82 to 2008-10 (online). http://www.ons.gov.uk/ons/publications/re- reference-tables.html?edition=tcm%3A77-223324. Accessed 16 Jan 2012.
18. Curtis L. Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, The University of Kent. 2011 (online). http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf. Accessed 16 Jan 2012.
19. Department of Health. NHS reference costs 2009-2010 (online). http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123459. Accessed 16 Jan 2012.
20. British National Formulary (BNF) 62 (online). 2011. http://bnf.org/bnf/ bnf/current/login.htm?uri=http%3A%2F%2Fbnf.org%2Fbnf%2Fbnf%2F57%2F104945.htm. Accessed 16 Jan 2012.
21. The NHS Information Centre. Prescription Cost Analysis, England. 2010 (online). http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/ prescriptions/prescription-cost-analysis-england - 2010. Accessed 12 Jan 2012.
22. NHS. Home Oxygen Service. 2012. http://www.homeoxygen.nhs.uk/1.php. Accessed 2 Feb 2012.
23. EuroQol Group. What is EQ-5D. 2012. http://www.euroqol.org/eq-5d/what-is- eq-5d.html. Accessed 2 Feb 2012.
24. Asukai Y, Baldwin M, Mungapen L. Utility values for COPD patients based on the EQ-5D questionnaire from three indacaterol Phase III studies [abstract P84]. Thorax. 2012;67 Suppl 2:A1-193 (Poster presented at British Thoracic Society Winter Meeting, London; 5-7 December 2012).
25. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736-41.
26. Rutten-van Mölken MP, Hoogendoorn M, Lamers L. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465-77.
27. Hart CL, Smith GD, Hole DJ, et al. Carboxyhaemoglobin concentration, smoking habit, and mortality in 25 years in the Renfrew/Paisley prospective cohort study. Heart. 2006;92(3):321-4.
28. Menotti A, Blackburn H, Seccareccia F, et al. The relation of chronic diseases to all-cause mortality risk - the Seven Countries Study. Ann Med. 1997;29(2):135-41.
29. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-37.
30. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
31. Curkendall SM, Lanes S, de Luise C, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol. 2006;21(11):803-13.
32. Department of Health (DH) and Health Protection Agency (HPA). Seasonal Flu Vaccine Uptake. https://www.wp.dh.gov.uk/winterwatch/files/2012/01/Seasonal- flu-GP-patients-Sept-to-Dec-2011.pdf. Accessed 2 Feb 2012.